A blood test that tells brain from spine injury joins a week of brain biomarkers

Telling one injury from another

The most immediately useful result of the week is a blood test that answers a question emergency teams ask often: is this a brain injury or a spine injury? In a preprint, serum brain-derived tau distinguishes traumatic brain injury from spinal cord injury with high accuracy, with an area under the curve of 0.91. Serum BD-tau significantly outperformed cerebrospinal fluid BD-tau for injury-type discrimination, with an area under the curve of 0.95 versus 0.80, and serum BD-tau showed superior discrimination of brain injury from spine injury compared to NfL, GFAP and UCH-L1, three established markers. The comparison that matters most is the first one: a blood test beating a spinal-fluid test. Blood is easier and safer to collect than cerebrospinal fluid, so a serum marker that outperforms the fluid marker is not a marginal improvement, it is a change in what a hospital can do at the bedside. The work is a preprint, so the numbers are the authors' own and need independent validation, but the direction is clear: brain-derived tau in blood carries information about which part of the nervous system is injured, not just that something is wrong. m:…0978

A second preprint adds a new candidate to the Alzheimer's blood-test race. Serum carboxymethyllysine levels are significantly lower in patients with clinically diagnosed Alzheimer's disease compared to healthy controls, the preprint reports. Each 1-ng/mL increase in serum CML is associated with lower odds of Alzheimer's disease, with an adjusted odds ratio of 0.727. Combining serum CML with p-tau217 improves diagnostic discrimination for Alzheimer's disease, reaching an area under the curve of 0.966. The interesting claim is not CML alone but the combination: two markers together discriminate better than either alone. CML is a molecule formed when sugars react with proteins, and lower levels being associated with disease is a reminder that a biomarker does not have to rise with illness to be useful. The combination needs testing where diagnosis is hardest, but an area under the curve of 0.966 is the kind of number that gets a follow-up study funded. m:…0977

Migraine's platelet link

The week's largest study, by case count, is about migraine rather than dementia. Higher platelet count is associated with an increased likelihood of migraine, a preprint reports, in an analysis across three cohorts. The UK Biobank discovery cohort of 18,919 cases showed an odds ratio of 1.058 for platelet count and migraine, and a meta-analysis of the NHANES and Framingham cohorts, with 1,887 and 395 cases, replicated the association with an odds ratio of 1.074. The effect sizes are small: an odds ratio just above 1 means each step up in platelet count is associated with a small increase in the likelihood of migraine. Small effects replicated across three cohorts are worth more than a large effect seen once, because replication is what separates a real association from a quirk of one dataset. The study does not show that platelets cause migraine, and it does not propose a treatment. What it does is point at a biological thread, the blood's clotting cells, that migraine researchers can now pull on with a specific question: is there a platelet pathway in migraine worth targeting, or is the association a marker of something else? m:…3429

A preprint meta-analysis on the neck's arteries adds a caution to the week's optimism about biomarkers. Carotid intima-media thickness, a measure of artery wall thickening, is associated with a 7% increase in dementia risk per one standard deviation increase, and the presence of 50-100% asymptomatic steno-occlusive disease is associated with a 48% increase in dementia risk. The numbers describe risk, not destiny, and they describe it in people without symptoms, which is the population where prevention would have to happen. But the same meta-analysis reports that current evidence from randomized controlled trials, including CREST-2, does not support carotid revascularization for the prevention of cognitive decline or dementia. Revascularization is a procedure to reopen a narrowed artery, and the trials say it does not prevent dementia even though the narrowing predicts it. That gap, between a risk factor and an intervention that does not work, is the honest core of the paper: knowing who is at risk is not the same as knowing how to help them. m:…2681

The postcode lottery

The week's final paper is not about a molecule but about a map. Substantial geographic variation in dementia diagnosis remains in England after accounting for differences in underlying disease prevalence, a preprint reports, using a Bayesian spatial analysis. Urbanicity, deprivation, ethnicity and healthcare provision are associated with variation in dementia case ascertainment, and areas of lower dementia case ascertainment exhibit higher proportions of undifferentiated dementia diagnoses. In plain terms: whether your dementia gets diagnosed, and how precisely, depends on where you live and who you are, even after allowing for how common the disease is in your area. An undifferentiated diagnosis is one that does not specify the type of dementia, which matters because treatment and care depend on the type. The paper's message sits uncomfortably next to the biomarker papers: blood tests that can distinguish injury types and flag Alzheimer's risk are arriving at the same time as evidence that diagnosis itself is unevenly distributed. A better test does not fix a system that does not offer it equally. The week's biomarkers are real progress, and the map is the reminder of what progress still has to reach. m:…6110